What is Veracyte?
Veracyte is a pioneering molecular diagnostics company dedicated to improving the diagnostic accuracy of cytology samples. By leveraging genomic technology, the firm provides clinicians with actionable insights that reduce the need for unnecessary surgical procedures. Its market position is defined by a commitment to minimally invasive diagnostics, which significantly enhances patient outcomes and reduces healthcare costs. The company's platform is designed to integrate seamlessly into existing clinical workflows, making it a critical partner for healthcare providers seeking to modernize diagnostic standards in oncology and beyond.
How much funding has Veracyte raised?
Veracyte has raised a total of $640.9M across 10 funding rounds:
Series B
$28M
Series C
$28M
Stock Offering
$58M
Share Placement
$40M
Debt
$45M
Stock Offering
$31.9M
Stock Offering
$55.1M
Stock Offering
$137.9M
Stock Offering
$194M
Series B (2010): $28M led by Versant Ventures, KPCB Holdings, TPG Biotech, and Domain Associates
Series C (2013): $28M supported by Domain Associates, TPG Biotech, GE Ventures, Versant Ventures, and KPCB Holdings
Stock Issuance/Offering (2013): $58M featuring Undisclosed
Share Placement (2015): $40M backed by Longwood Capital Partners, Deerfield, venBio, Camber Capital, and Broadfin Capital
Debt (2016): $45M with participation from Visium Healthcare Partners
Stock Issuance/Offering (2016): $31.9M led by Undisclosed
Stock Issuance/Offering (2018): $55.1M supported by Undisclosed
Stock Issuance/Offering (2019): $137.9M featuring Undisclosed
Stock Issuance/Offering (2020): $194M backed by Undisclosed
Key Investors in Veracyte
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies around the world, managing over $5.5 billion in assets.
KPCB Holdings
Kleiner Perkins is a Menlo Park-based venture capital firm that invests in early and growth-stage technology and life science companies, providing capital and operational support.
TPG Biotechnology Partners
TPG is a global alternative asset management firm that partners with businesses to drive long-term value creation across multiple industries and investment stages.
What's next for Veracyte?
Looking ahead, Veracyte is well-positioned to leverage its substantial capital base to accelerate the adoption of its molecular tests globally. The strategic focus remains on expanding the clinical evidence base for its existing diagnostic suite while exploring new therapeutic areas where molecular cytology can provide superior diagnostic clarity. As the company continues to scale, it is expected to prioritize operational efficiency and strategic partnerships that further solidify its dominance in the molecular diagnostics market, ensuring that its innovative solutions remain at the forefront of patient care.
See full Veracyte company page
